Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

Novo Nordisk Sees 3% Hit to Sales in 2022 from China Volume Based Procurement

26/11 07:07


  • (PLX AI) – Novo Nordisk announces impact from Volume Based Procurement for insulin in China.
  • • Novo Nordisk expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China
  • • The VBP for insulin is expected to be implemented during the first half of 2022
  • • Novo Nordisk will provide the financial outlook for 2022 in connection with the announcement of the full-year 2021 results on 2 February 2022